VORANIGO Film-coated tablet Ref.[115788] Active ingredients: Vorasidenib

Source: European Medicines Agency (EU)  Revision Year: 2025  Publisher: Les Laboratoires Servier, 50, rue Carnot, 92284 Suresnes cedex, France

Product name and form

Voranigo 10 mg film-coated tablets.

Voranigo 40 mg film-coated tablets.

Pharmaceutical Form

Film-coated tablet.

Voranigo 10 mg film-coated tablets: White to off-white, round tablets with a 6 mm diameter, imprinted with '10' on one side.

Voranigo 40 mg film-coated tablets: White to off-white, oblong tablets with a length of 14.8 mm and width of 6.3 mm, imprinted with '40' on one side.

Qualitative and quantitative composition

Voranigo 10 mg film-coated tablets

Each film-coated tablet contains 10 mg of vorasidenib (as hemicitric acid, hemihydrate).

Excipient with known effect: Each film-coated tablet contains lactose monohydrate, equivalent to 0.60 mg lactose (see section 4.4).

Voranigo 40 mg film-coated tablets

Each film-coated tablet contains 40 mg of vorasidenib (as hemicitric acid, hemihydrate).

Excipient with known effect: Each film-coated tablet contains lactose monohydrate, equivalent to 2.39 mg lactose (see section 4.4).

For the full list of excipients, see section 6.1.

Active Ingredient

Vorasidenib is an inhibitor that targets the mutant IDH1 and IDH2 enzymes. In patients with astrocytoma or oligodendroglioma, IDH1 and IDH2 mutations lead to overproduction of the oncogenic metabolite 2-hydroxyglutarate (2-HG), resulting in impaired cellular differentiation contributing to oncogenesis. Inhibition of the IDH1- and IDH2-mutated proteins by vorasidenib inhibits the abnormal production of 2-HG leading to differentiation of malignant cells and a reduction in their proliferation.

List of Excipients

Tablet core:

Microcrystalline cellulose (E460)
Croscarmellose sodium
Silicified microcrystalline cellulose (contains microcrystalline cellulose and silica colloidal anhydrous)
Magnesium stearate (E470b)
Sodium lauryl sulfate (E487)

Tablet film-coating:

Hypromellose
Titanium dioxide (E171)
Lactose monohydrate
Macrogol (E1521)

Printing ink:

Black iron oxide (E172)
Propylene glycol (E1520)
Hypromellose (E464)

Pack sizes and marketing

White HDPE bottle with a polypropylene (PP) child-resistant closure and polyethylene (PE) faced induction heat seal liner including three silica gel desiccants in HDPE canisters. Pack-size of 30 film-coated tablets.

Marketing authorization holder

Les Laboratoires Servier, 50, rue Carnot, 92284 Suresnes cedex, France

Marketing authorization dates and numbers

EU/1/25/1912/001
EU/1/25/1912/002

Drugs

Drug Countries
VORANIGO Austria, Estonia, Lithuania, United Kingdom, United States

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.